Performance indicators and validity of serum fructosamine assay as a diagnostic test in a screening program for diabetes mellitus

Saudi Medical Journal

Volumn 24, Issue 5, 2003, Pages 477-484

  Mula Abed, Waad Allah Sharef ^a   Al Naemi, Amjad H ^a  

^a UNIVERSITY OF MOSUL   (Iraq)

Author keywords

[No Author keywords available]

Indexed keywords

FRUCTOSAMINE; GLUCOSE;

ADULT; ARTICLE; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; FEMALE; FRUCTOSAMINE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; INTERMETHOD COMPARISON; IRAQ; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MALE; ORAL GLUCOSE TOLERANCE TEST; RURAL AREA; SCREENING TEST; SENSITIVITY AND SPECIFICITY; URBAN AREA; VALIDATION PROCESS; WORLD HEALTH ORGANIZATION;

ADULT; BLOOD GLUCOSE; DIABETES MELLITUS; FASTING; FEMALE; FRUCTOSAMINE; GLUCOSE INTOLERANCE; HUMANS; MALE; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 0038692915     PISSN: 03795284     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. King H, Rewers M. WHO Ad Hoc Diabetes Reporting Group: global estimates for prevalence of diabetes mellitus and impaired glucose tolerance in adults. Diabetes Care 1993; 16: 157-177.
2. Modan M, Harris MI. Fasting plasma glucose in screening for NIDDM in the U.S. Diabetes Care 1994; 17: 436-439.
3. Reid MC, Sox HC, Comi R, Atkins D. Screening for diabetes mellitus. U.S. Preventive Services Task Force, Guidelines from Guide to Clinical Preventive Services. Lippincott Williams & Wilkins; 1996. p.. http://www.mdconsult.com.
4. Hodge JE. The Amadori rearrangement. Adv Carbohydr Chem 1953; 10: 169-205.
5. Armbruster DA. Fructosamine: structure, analysis and clinical usefulness. Clin Chem 1987; 33: 2153-2163.
6. Hodge JE, Rist CE. The Amadori rearrangement under new conditions and its significance for non-enzymatic browning reactions. J Am Chem Soc 1953; 75: 316-322.
7. Schleicher E, Wieland OH. Specific quantitative by HPLC of protein (lysine) bound glucose in human serum albumin and other glycosylated proteins. J Clin Chem Clin Biochem 1981; 19: 81-86.
8. Johnson RN, Metcalf PA, Baker JR. Fructosamine: a new approach to the estimation of serum glycosylprotein. An index of diabetic control. Clin Chim Acta 1983; 127: 87-95.
9. Dolhofer R, Wieland OH. Glycosylation of serum albumin: elevated glycosyl-albumin in diabetic patients (Letter). FEBS 1979; 103: 282-286.
10. Baker JR, O'Connor JP, Metcalf PA, Lawson MR, Johnson RN. Clinical usefulness of estimation of serum fructosamine concentration as a screening test for diabetes mellitus. Br Med J 1983; 287: 863-867.
11. Baker JR, Johnson RN, Scott DJ. Serum fructosamine concentrations in patients with type II (non-insulin-dependent) diabetes mellitus during changes in management. Br Med J 1984; 283: 1484-1486.
12. Mula-Abed WS, Abdul-Razzak NA. Serum fructosamine measurement as an index of glycaemic state in Iraqi diabetics. Bahrain Med Bull 1999; 21: 130-134.
13. Mula-Abed WS, Tsang WM, Miller A, Kurtz A. Comparison of glycosylated haemoglobin and fructosamine assay as indices of glycaemic control in diabetic patients. Saudi Med J 1989; 10: 216-220.
14. Engelgau MM, Thompson TJ, Herman WH, Boyle JP, Aubert RE, Kenny SJ et al. Comparison of fasting and 2-hour glucose and HbA1c levels for diagnosing diabetes. Diagnostic criteria and performance revisited. Diabetes Care 1997; 20: 785-791.
15. Guillausseau PJ, Charles MM, Paolaggi F, Timsit J, Chanson P, Peynet J et al. Comparison of HbA1 and fructosamine in diagnosis of glucose-tolerance abnormalities. Diabetes Care 1990; 13: 898-900.
16. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20: 1183-1197.
17. World Health Organization (WHO). Diabetes mellitus: report of a WHO Study Group. Tech Rep Ser No. 727: Geneva; 1985.
18. Tietz NW, Burtis CA, Ashwood ER. Textbook of Clinical Chemistry, 2nd ed. Philadelphia (PA): WB Saunders; 1994. p. 700-704, 958-965.
19. Howey JEA, Browning MCK, Fraser CG. Assay of serum fructosamin that minimizes standardization and matrix problems: Use to assess components of biological variation. Clin Chem 1987; 33: 269-272.
20. Gordis L. Epidemiology. Philadelphia (PA): WB Saunders; 1996. p. 59-70.
21. Armitage P. Statistical methods in medical research. 4th ed. Oxford, London (UK): Blackwell Scientific Publications; 1974. p. 106.
22. Young RJ. The clinical need for HbA1c standardization. Ann Clin Biochem 2000; 37: 47-48.
23. Marshall SM, Barth JH. Standardization of HbA1c measurements: a consensus statement. Ann Clin Biochem 2000; 37: 45-46.
24. Lloyd D, Marples J. Simple colorimetry of glycated serum protein in a centrifugal analyzer. Clin Chem 1984; 30: 1686-1688.
25. Comtois R, Desjarlais F, Nguyen M, Beauregard H. Clinical usefulness of estimation of serum fructosamine concentration as screening test for gestational diabetes. Am J Obstet Gynaecol 1989; 160: 651-654.
26. Roberts AB, Baker J. Serum fructosamine: A screening test for diabetes in pregnancy. Am J Obstet Gynaecol 1986; 154: 1027-1030.
27. Dunn PJ, Cole RA, Soeldner JS, Gleeson RE. Reproducibility of hemoglobin A1c and sensitivity to various degrees of glucose intolerance. Ann Intern Med 1979; 91: 390-396.
28. Santiago JV, Davis JE, Fisher F. Hemoglobin A1C levels in a diabetes detection program. J Clin Endocrinol Metab 1978; 47: 578-580.
29. Salemans THB, Van Dieijen-Visser MP, Brombacher PJ. The value of HbA1 and fructosamine in predicting impaired glucose tolerance: an alternative to OGTT. Ann Clin Biochem 1987; 24: 447-452.
30. Tsuji I, Nakamoto K, Hasegawa T, Hisashige A, Inawashiro H, Fukao A et al. Receiver operating characteristic analysis on fasting plasma glucose, HbA1c, and fructosamine on diabetes screening. Diabetes Care 1991; 14: 1075-1077.
31. Ko GT, Chan JC, Yeung VT, Show CC, Tsang LW, Li JK et al. Combined use of a fasting plasma glucose concentration and HbA1c or fructosamine predicts the likelihood of having diabetes in high-risk subjects. Diabetes Care 1998; 21: 1221-1225.